Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Brisbane, California 94005


Purpose:

Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL) International study with sites in the Czech Republic and Poland


Criteria:

- Relapsed or progressive low-grade/follicular NHL who are candidates for rituximab therapy - Patients who were on other therapy including CHOP or radiation - Previous therapy must have concluded 30 days prior to enrollment - Demonstrable CD20-positive tumor population in lymph nodes or bone marrow


NCT ID:

NCT00057447


Primary Contact:

Study Director
Williamson Bradford, MD
InterMune


Backup Contact:

N/A


Location Contact:

Brisbane, California 94005
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 12, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.